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Abstract
Background: Despite medical advances, major surgery remains high risk. Up to 44% of patients experience
postoperative complications, which can have huge impacts for patients and the healthcare system. Early
recognition of postoperative complications is crucial in reducing morbidity and preventing long-term
disability. The current standard of care is intermittent manual vital signs monitoring, but new wearable
remote monitors offer the benefits of continuous vital signs monitoring without limiting the patient’s
mobility. The aim of this study is to evaluate the feasibility, acceptability and clinical impacts of continuous
remote monitoring after major surgery.
Methods: The study is a randomised, controlled, unblinded, parallel group, feasibility trial. Adult patients
undergoing elective major surgery will be invited to participate if they have the capacity to provided
informed, written consent and do not have a cardiac pacemaker or an allergy to adhesives. Participants will
be randomly assigned to receive continuous remote monitoring and normal National Early Warning Score
(NEWS) monitoring (intervention group) or normal NEWS monitoring alone (control group). Continuous
remote monitoring will be achieved using the SensiumVitals® wireless patch which is worn on the patient’s
chest and monitors heart rate, respiratory rate and temperature continuously and alerts the nurse when
there is deviation from pre-set physiological norms. Participants will be followed up throughout their
hospital admission and for 30 days after discharge. Feasibility will be assessed by evaluating recruitment
rate, adherence to protocol and randomisation, and the amount of missing data. The acceptability of the
patch to nursing staff and patients will be assessed using questionnaires and interviews. Clinical outcomes
will include time to antibiotics in cases of sepsis, length of hospital stay, number of critical care admissions
and rate of readmission within 30 days of discharge.
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Discussion: Early detection and treatment of complications minimises the need for critical care, improves
patient outcomes, and produces significant cost savings for the healthcare system. Remote continuous
monitoring systems have the potential to allow earlier detection of complications, but evidence from the
literature is mixed. Demonstrating significant benefit over intermittent monitoring to offset the practical and
economic implications of continuous monitoring requires well-controlled studies in high-risk populations to
demonstrate significant differences in clinical outcomes; this feasibility trial seeks to provide evidence of
how best to conduct such a confirmatory trial.
Trial registration: This study is listed on the ISRCTN registry with study ID ISRCTN16601772.
Keywords: Continuous, Early warning score, Vital signs, Monitoring, Surgery, Complications
Background
Patients having major surgery are at high risk of compli-
cations, some of which can be life-threatening. Rates of
complications have been found to be as high as 33–44%
in patients undergoing surgery for gastrointestinal
cancers [1]. Patients who develop postoperative compli-
cations become progressively unwell, often over a short
period of time. Early recognition of postoperative com-
plications is crucial in reducing morbidity and prevent-
ing long term-disability; for patients with septic shock,
there is an 8% increase in mortality for every hour of
delay in antibiotic administration [2].
The more unwell a patient becomes, the more likely they
are to require higher level care, on either high-dependency
units (HDU; level II) or intensive care units (ICU; level III).
Escalation of care comes at significant cost to both the pa-
tient and the health service and is associated with worse
patient outcomes. The average cost of a level I (general
ward) bed is £433/day, as compared to £1033/day for a
HDU bed, and £1351/day for an intensive care bed [3].
Early detection and treatment of complications minimises
the need for level II/III care, improves patient outcomes
and produces significant cost savings.
One of the ways patients are monitored for complica-
tions is by recording on a chart their vital signs. The vital
signs are used to form a score, the National Early Warning
Score (NEWS), which can alert if the patient becomes
unwell. The vital signs included in the NEWS score are
blood pressure, heart rate, breathing rate, oxygen satur-
ation, level of consciousness and temperature [4]. The
NEWS score also takes into account the need for supple-
mentary oxygen to maintain a patient’s saturations. Typic-
ally, in the postoperative period, NEWS will be calculated
half hourly for the first few hours, and if the patient re-
mains stable, the frequency will decrease to 2-hourly and
then 4-hourly, until the patient is ready for discharge
when the NEWS may be recorded only twice a day.
Although NEWS has proven benefit, it suffers from
several drawbacks. A 2012 study evaluated early warning
scores in patients 48 h before an adverse event [5]. Of
patients, 81% had a score indicative of deterioration, but
recordings were ‘mostly incomplete’ with respiratory rate
documented in ‘only 30% to 66%’. NEWS relies on man-
ual observations, is time-consuming, and open to user
interpretation. Vital signs are taken at predetermined in-
tervals (typically 4-hourly), with patient deterioration
possible between recordings. It has been suggested that
the gap between observations is one of the primary fail-
ings of the NEWS system [6].
A solution to the problem of inadequate monitoring fre-
quency is continuous monitoring at the bedside. Continu-
ous monitoring is used in level II/III care, but is limited by
“hard-wired” equipment, which tethers the patient to the
bed space. This hinders patient mobility and potentially
slows their recovery. One study tested ICU-style monitor-
ing on a general ward and found that only 16% of patients
remained connected in a 72-h period [7].
A number of systems have been designed that
combine the benefits of a wearable, wireless patch with
continuous monitoring of vital signs. One such device is
the SensiumVitals® which monitors heart rate, respira-
tory rate and temperature continuously. The data are
transmitted wirelessly every 2 min to a mobile device
carried by the nurse which alerts when there is deviation
from pre-set physiological norms.
It is hypothesised that the remote continuous monitor-
ing system, as an adjunct to standard NEWS monitoring,
will allow earlier detection of postoperative complications.
This should reduce morbidity, which in turn should result
in a decreased need for high dependency/intensive care.
Studies evaluating continuous monitoring of multiple
vital signs parameters have shown mixed results. There is a
preponderance of observational studies, which means that
causal associations between interventions and patient
outcomes have to be interpreted with care. An
industry-funded controlled before-and-after study of 7643
patients [8] found that continuous monitoring on a
medical-surgical unit was associated with a decrease in total
ICU days, but the rate of ICU admission was unchanged.
The three largest randomised controlled trials in this area
show conflicting results but share common limitations. A
randomised controlled trial of 402 high-risk medical and
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surgical patients found that continuous multi-parameter
monitoring showed no effect on adverse events or mortality
[9]. However, only 16% of the patients were continuously
monitored for the full 72 h intended. Patient and staff
compliance may have influenced the impact of the inter-
ventions. This trial was also underpowered to detect differ-
ences in clinical outcome measures given the complex
nature of the intervention under investigation.
Demonstrating significant benefit over intermittent
monitoring to offset the practical and economic
implications of continuous monitoring is difficult and re-
quires large, well-controlled studies in high-risk popula-
tions to demonstrate significant differences in clinical
outcomes, such as critical care admissions. Given the
complexity of the intervention, before a definitive trial is
designed, there is the need for a feasibility study focussed
not only on clinical outcome measures but also patient
and nursing acceptability and compliance. Compliance is
unpredictable yet crucial to the adequate assessment of
the intervention. If the patient or nursing staff refuse to
engage with the monitoring device, this will negate the
need for a definitive trial. In addition, a feasibility study
will allow the identification of barriers to recruitment and
protocol adherence and allow optimisation of the trial de-
sign and the technology itself.
Aims
The main aim is to determine the feasibility of perform-
ing a large-scale randomised controlled trial of continu-
ous remote monitoring after major surgery. A secondary
objective is to evaluate the safety, potential efficacy and
acceptability of a wearable, remote monitoring system
for patients after major surgery, as compared to standard
monitoring with the NEWS system alone.
Trial design
This is a single-centre, feasibility, randomised, con-
trolled, parallel group trial of continuous remote vital
signs monitoring for patients who have undergone major
elective general surgery. Participants will be individually
randomised on a 1:1 basis to receive either remote mon-
itoring plus NEWS or monitoring by NEWS alone. Ran-
domisation will use random permuted blocks and be
stratified by ASA (American Society of Anaesthesiolo-
gists comorbidity score) and gender.
Methods
Study setting
All participants will be recruited from St James’s
University Hospital, Leeds, UK.
Inclusion criteria
 Patients who are undergoing elective surgery
 Patients who have the capacity to provide
informed, written consent on admission
 All ages ≥ 18 years
Exclusion criteria
 Patients who have undergone emergency surgery
 Allergy to adhesives on electrodes
 Cardiac pacemaker in situ
Recruitment
Patients will be selected on the basis that they are undergo-
ing elective major abdominal surgery and are anticipated to
return to one of the participating wards afterwards. Types
of surgery can include, but are not limited to, colorectal,
upper gastrointestinal, liver, pancreas and biliary surgeries.
Table 1 illustrates the participant timeline for this
study. Patients will be identified, recruited and con-
sented for inclusion in the trial on the day of their sur-
gery. This will take place on the General Surgical
Admissions Lounge where patients attend on the morn-
ing of their elective procedures.
The patients will be given information in the form of a
patient information sheet regarding the study. Following
a period of consideration, if they consent to participate
in the study, they will be randomised into one of two
monitoring arms.
Randomisation
Following confirmation of eligibility and written in-
formed consent, participants will be randomised into the
trial by an authorised member of staff at the research
site. Randomisation will be performed centrally using
the University of Leeds Clinical Trials Research Unit
(CTRU) 24-h randomisation service, either via the tele-
phone or the CTRU website.
Participants will be randomised on a 1:1 basis and will
be allocated a unique trial number. Randomisation will
be conducted using stratified block randomisation with
variable block size with sex (male/female) and ASA
grade (grades 1–4) as stratification factors.
The randomisation sequence will be provided by a
statistician in the Leeds Clinical Trials Research Unit
and computer generated using SAS 9.4 (SAS Institute
Inc., USA, 2013). This sequence will be implemented
and delivered by programmers through the Leeds CTRU
Gen24 system, a dedicated telephone and web-based
randomisation service.
Interventions
Patients randomised to the ‘intervention’ arm will re-
ceive a patch and standard NEWS monitoring.
When the patient comes out of theatre, they are nursed
in Recovery for a short time before being admitted on to
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the receiving ward. The patients allocated to receive the
remote monitoring will, where possible, have the patch ap-
plied in Recovery by a member of the research team. If for
any reason the patch cannot be applied in Recovery, it will
be applied as soon as possible upon the patient’s return to
one of the participating wards. If a participant is admitted
to level II/III care after surgery and before returning to a
participating ward, they will have the patch applied in Re-
covery but the patch will only be activated once the pa-
tient returns to the participating ward. This will usually be
1–2 days later.
Two colorectal surgery wards will be participating in
the study: male and female. The male ward houses 25
beds, whilst the female ward houses 28 beds.
The patch will activate on arrival on the ward, and the
patient’s nurse will carry a mobile device to alert them if
the vital signs stray outside of normal parameters.
Remote monitoring data will also be accessible on the
ward computer screens for wider access. There will be
no dedicated telemetry screen for the patch data.
Nursing staff will be provided with thorough training
before the commencement of the study. This will involve
training in the application and removal of the patch, the
use of the mobile application and how to acknowledge
alerts. If the mobile devices alert the nursing staff to ab-
normal vital signs, the ensuing clinical response is not
mandated, but left to the nurse’s discretion.
In order to monitor alarm burden, the Clinical Fellow
assigned to the trial will make daily ward visits and ask
the nursing staff about false alerts. The Fellow will then
adjust the monitor’s delays and thresholds on an individ-
ual basis and according to clinical need, for instance,
adjusting the heart rate alert threshold in patients with
pre-existing cardiac arrhythmias.
Table 1 Schedule of enrolment, interventions, and assessments
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During these daily ward visits, the Fellow and the re-
search nurse will also be responsible for changing expired
patches and removing patches upon patient discharge. In
order to optimise patient comfort and compliance with
the device, it will also be possible to adjust or replace elec-
trodes, including after patient washing.
Patients in the ‘control’ arm will receive standard
NEWS monitoring alone. All usual nursing and medical
care are permitted within both arms of the trial.
Blinding
Blinding is not applicable for this study. Neither the pa-
tients nor the nursing staff can be blinded to the inter-
vention received. The data collection will be performed
by a research nurse and clinical fellow, who will both be
administering the monitoring device, and so are neces-
sarily unblinded. However, the objective methods of col-
lecting the outcome data minimise the risk of bias.
These data will be taken from the clinical records made
by the patients’ usual care teams, including a succession
of junior medical staff on rotation, who will be unaware
of the study. In addition, the predefined criteria for the
outcome measures provide minimal scope for interpret-
ation of their presence or absence by the data collection
team. The clinical fellow will be performing the analysis
alongside an unblinded statistician.
Data collection
The patients will remain in their allocated study arm for
the duration of their hospital stay. If a remotely moni-
tored patient is moved to a critical care bed during their
admission, the remote monitoring will be temporarily
suspended pending reinstatement depending whether
they return to a participating ward. Every effort will be
made to ensure that participants remain in the study
arm to which they were originally allocated, and any
non-compliance will be recorded.
Patients’ participation in the trial will end when they
are discharged from hospital. At this point, remotely
monitored patients will be invited to complete a ques-
tionnaire regarding their experiences of wearing the
patch (see Appendix 1). Information regarding the ad-
mission will be collected once the patient has left hos-
pital. Information will also be collected regarding the
number of patients who agree to take part in the study,
those who do not and the reason for not taking part.
The nursing staff (registered nurses and healthcare
assistants) will be invited to complete a paper question-
naire about system usability (see Appendix 2). They will
also be invited to undertake a semi-structured interview
regarding their experience of providing the new moni-
toring system based on a purposive sampling strategy,
to get the most comprehensive impression of nursing
perceptions. This purposive sample will include nurses
at various grades and with different experiences of the
device.
Primary outcome measures
 Recruitment rate, including proportion of ineligible
patients and reasons for non-consent
 Information on the ideal method of randomisation,
which will include calculation of intra-cluster
correlation co-efficient to investigate whether
there is any inherent clustering in outcomes
based on which ward bay a participant is
admitted to
 Adherence to protocol, and reasons for non-
adherence, as defined by the number of patients
who do not receive the correct type of monitoring
as per randomisation (and reasons for this) and the
number of patients who do not wear the patch for
their entire hospital stay or at least 5 days during
their admission
 Amount of missing clinical data, as collected on
the Case Report Forms, and loss-to-follow-up
 Optimal outcome measures to test effectiveness (see
secondary outcome measures)
 Estimation of parameters to input into the sample
size calculation for a definitive RCT.
Secondary outcome measures
 Time to antibiotics in cases of sepsis
 Number of HDU/ICU admissions
 Length of stay in HDU/ICU
 Total length of stay in hospital
 Number of postoperative complications, defined and
scored according to the Clavien-Dindo classification
of surgical complications [10]
 Number of reinterventions, defined and scored
according to the Clavien-Dindo classification of
surgical complications [10]
 Patient acceptability using questionnaire scores
 Number of patients not wearing patch for at least
5 days
 Nursing acceptability using questionnaire scores and
thematic analysis of interviews
 30-day readmission rate
Sample size and expected accrual
As the trial is designed to assess the feasibility of con-
ducting a future definitive large-scale trial, a formal
power calculation is not considered appropriate as ef-
fectiveness is not being formally evaluated.
According to the findings of Teare et al. [11], at least
120 subjects (60 in each group) will be required in the
feasibility RCT to estimate event rates in the intervention
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arm with adequate precision. Anticipating an estimated
consent rate of 30–50%, between 240 and 400 patients will
be approached in order to recruit 120 participants.
In addition, it is possible that not all participants will
be assigned a bed in a participating ward. Allowing for
20% of patients going to non-participating wards, with
the expectation that this is likely to be balanced between
the study groups, this necessitates that 300 to 500 pa-
tients will need to be approached and approximately 150
participants randomised in order to have monitoring
data on 120 participants in total. With a 12-month re-
cruitment period, this equates to 6–10 patients being
approached on average per week.
Patients who are not admitted to a participating ward
will be classed as ‘drop-out’ due to design and will not
be included in the modified intention-to-treat analysis.
Planned analyses
Analyses have been pre-specified in a statistical analysis
plan. The analysis of the primary and secondary out-
come measures will take place when all participants have
been followed up (i.e. 30 days after the last recruited
participant’s date of discharge). No interim analyses are
planned but safety data will be presented to the Multi-
disciplinary Advisory Group at regular intervals.
Analysis will be carried out following the principles of
modified intention-to-treat (ITT). The modified ITT
(mITT) population will include all participants rando-
mised to the trial, analysed according to the treatment
group to which they were randomised, regardless of ad-
herence to the protocol. The mITT population will not
include any participants who are classed as ‘drop-out’
due to design (i.e. those who were never admitted to a
participating ward).
As this is a feasibility study, no formal comparison be-
tween the study arms will be undertaken. Summaries will
be produced by subgroup to determine any differences be-
tween low- and high-risk patients. High-risk patients will
be defined as ASA > 2 undergoing major + surgery or
ASA = > 2 with a perioperative critical care admission.
Baseline characteristics will be summarised descrip-
tively overall and by trial arm. No statistical comparison
between trial arms will be made.
Quantitative secondary outcome measures will be
summarised descriptively using appropriate summary
statistics both overall and by trial arm (mean, stand-
ard deviation, range and median for continuous out-
comes and frequency and percentages for categorical
measures). Proportions of missing data will also be
presented. Data from patients discharged before the
5 days has elapsed will be censored. Qualitative sec-
ondary outcomes including patient acceptability and
nurse acceptability will be analysed using a thematic
analysis approach.
Safety
As this is a feasibility study, data will be monitored pro-
spectively by the research team. Any clinical concerns or
complications occurring in excess of those normally ex-
perienced after this type of surgery will be reported by
the Chief Investigator to the Sponsor and appropriate
action taken to suspend or terminate the study until
such time that patient safety can be assured in line with
national guidelines for patient outcomes in surgery.
Data management
Personal data collection during the study will be handled
in accordance with Data Protection Act 1998. All infor-
mation collected during the course of the trial will be
kept strictly confidential.
Information will be held securely on paper and elec-
tronically at Leeds Teaching Hospitals NHS Trust and
the University of Leeds Clinical Trials Research Unit
(CTRU). The study site will maintain a file of essential
trial documentation and will keep copies of completed
case report forms (CRFs) for the trial. Completed CRFs
will be sent to the CTRU for entry onto the secure trial
database.
All vital signs data collected by the SensiumVitals® sys-
tem are stored and retained on the hospital network.
The SensiumVitals® system inherits all the hospital se-
curity procedures and data backup policies, to ensure
data access and servers are secured.
In line with the principles of Good Clinical Practice
guidelines, at the end of the trial, data will be securely
archived for a minimum of 5 years.
Data monitoring and validation
Day to day monitoring for completeness and quality
of trial data will be conducted centrally at the CTRU
by the Data Manager or their delegate. Every effort
will be made to ensure that as much data as possible
are available and that reasons for unobtainable data
are recorded.
For a feasibility study of this nature and duration, a
separate Data Monitoring and Ethics Committee is not
required. The Multidisciplinary Advisory Group will
meet approximately monthly and review screening, re-
cruitment, site monitoring, data quality, protocol com-
pliance and withdrawals.
The data manager (or their delegate) will perform veri-
fication of the forms in real time, as data are received, in
accordance with the guidelines developed for the study.
This will ensure that data are complete, consistent and
up-to-date. Key data items will be 100% checked by the
data manager or their delegate. In addition, statistical
checks will be used to validate the data and check for
any missing or inconsistent data.
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Progression criteria
The criteria for progression to a definitive randomised
controlled trial will be as follows:
 The recruitment of 120 patients within 12 months
who receive monitoring on the trial
 Missing data limited to no more than 20% attrition
Dissemination
The trial results will be disseminated in a published
manuscript and through presentation to clinical and
patient and public forums with the aim of reaching
healthcare workers and other stakeholders throughout
the healthcare system.
Discussion
Although continuous monitoring is routinely used in
high-dependency care, it has practical implications
which have to be offset in the general ward setting.
Many of the existing clinical studies were limited by the
complex nature of the intervention under investigation.
Patient and staff compliance may have influenced the
impact of the interventions. In order to ensure
maximum benefit from continuous monitoring tech-
nologies, it is crucial to engage patients and nursing staff
in the implementation and, ideally, development of the
intervention.
Previous studies have found the main barriers to
the implementation of remote monitoring are nursing
engagement and alarm burden [8]. In this trial, these
issues will be addressed through a concurrent process
evaluation. Nurses will be provided with thorough
training, and their engagement in the use of the de-
vice and perceptions of the adequacy of the training
will be explored through the questionnaire and inter-
views. False alert rates will be monitored on a daily
basis and delays and thresholds will be adjusted ac-
cordingly. Patient satisfaction will also be assessed in
order to optimise the patient’s comfort and compli-
ance with the device.
Demonstrating significant benefit over intermittent
monitoring to offset the practical and economic implica-
tions of continuous monitoring requires the optimisation
of the intervention to the mutual satisfaction of nursing
staff and patients alike. This feasibility study will focus
on not only clinical outcome measures but also patient
and nursing acceptability and compliance with the inter-
vention. This will allow the identification of barriers to
recruitment and protocol adherence and allow optimisa-
tion of the definitive trial protocol.
Trial status
At the time of submission, TRaCINg is open to
recruitment.
Appendix 1
Table 2 Patient experience questionnaire
Statement Strongly
agree







I felt safer because my
vital signs were being
monitored constantly.
We welcome any additional comments you may have:
Appendix 2





I think that I would like to
use this product again
1 2 3 4 5
I found the product
unnecessarily complex
1 2 3 4 5
I thought the product was
easy to use
1 2 3 4 5
I think that I would need
the support of a technical
person to be able to use
this product
1 2 3 4 5
I found that the various
functions in this product
were well integrated
1 2 3 4 5
I thought that there was
too much inconsistency
in this product
1 2 3 4 5
I would imagine that
most people would
learn to use this product
very quickly
1 2 3 4 5
I found the product very
awkward to use
1 2 3 4 5
I felt very confident using
the product
1 2 3 4 5
I needed to learn a lot of
things before I could get
going with this product
1 2 3 4 5
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